Lixisenatide

Lixisenatide is a combination of a long-acting human insulin analog with a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) or lixisenatide

Indications

It is indicated for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in patients who are not controlled on existing therapy. In combination with the following oral antidiabetics or basal insulin

Dosage

INJ ECTABLE, S.C.; the starting dose is 10 mcg (µg) LIXISENATIDE once daily for 14 days. Then, the LIXISENATIDE dose should be increased to 20 mcg once daily, which is the maintenance dose.

Contra-Indications

Hypersensitivity; hypoglycemic episodes

Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established Pregnancy: Data not sufficient; not to be used Lactation: Data not sufficient; not to be used Elderly: No dose adjustment is required based on age.

Side Effects

hypoglycemia, allergic reactions, nausea, nasopharyngitis, diarrhea, upper respiratory tract infection, headache

Drug Interactions

along with other glucose lowering drugs, adrenergic drugs